The Long Non-coding RNA LINC01013 Enhances Invasion of Human Anaplastic Large-cell Lymphoma

Overview

Journal Sci Rep

Specialty Science

Date 2017 Mar 24

PMID 28331184

Citations 23

Authors

I-Hsiao Chung

Pei-Hsuan Lu

Yang-Hsiang Lin

Ming-Ming Tsai

Yun-Wen Lin

Chau-Ting Yeh

Kwang-Huei Lin

Affiliations

Soon will be listed here.

Abstract

Anaplastic large-cell lymphoma (ALCL) is a rare type of highly malignant, non-Hodgkin lymphoma (NHL). Currently, only studies on the chimeric oncogene NPM-ALK have reported a link to ALCL progression. However, the specific molecular mechanisms underlying the invasion of ALCL are still unclear. Here, we sought to investigate differentially expressed, long non-coding RNAs (lncRNAs) in ALCL and their potential biological function. Our microarray analyses revealed that LINC01013, a novel non-coding RNA gene, was highly expressed in clinical specimens of ALCL and was significantly upregulated in invasive ALCL cell lines. Knockdown of LINC01013 suppressed tumor cell invasion; conversely, its overexpression enhanced tumor cell invasion. LINC01013-induced invasion was mediated by activation of the epithelial-to-mesenchymal transition (EMT)-associated proteins, snail and fibronectin. Specifically, LINC01013 induced snail, resulting in activation of fibronectin and enhanced ALCL cell invasion. Collectively, these findings support a potential role for LINC01013 in cancer cell invasion through the snail-fibronectin activation cascade and suggest that LINC01013 could potentially be utilized as a metastasis marker in ALCL.

Citing Articles

Differential Expression of lncRNAs in HIV Patients with TB and HIV-TB with Anti-Retroviral Treatment.

Reid V, Ramos E, Veerapandian R, Carmona A, Gadad S, Dhandayuthapani S Noncoding RNA. 2024; 10(4).

PMID: 39051374 PMC: 11270221. DOI: 10.3390/ncrna10040040.

Investigation of long non-coding RNAs in extracellular vesicles from low-volume blood serum specimens of colorectal cancer patients.

Boudna M, Machackova T, Vychytilova-Faltejskova P, Trachtova K, Bartosova R, Catela Ivkovic T Clin Exp Med. 2024; 24(1):67.

PMID: 38568288 PMC: 10991038. DOI: 10.1007/s10238-024-01323-1.

Histone modification of endothelial-mesenchymal transition in cardiovascular diseases.

Jun Q, Youhong L, Yuan Z, Xi Y, Wang B, Xinyi S Front Cardiovasc Med. 2022; 9:1022988.

PMID: 36568553 PMC: 9768231. DOI: 10.3389/fcvm.2022.1022988.

LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide.

Quaife N, Chothani S, Schulz J, Lindberg E, Vanezis K, Adami E J Cardiovasc Transl Res. 2022; 16(1):77-85.

PMID: 35759180 PMC: 9944705. DOI: 10.1007/s12265-022-10288-z.

Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer.

Xue M, Wang Y, Wang J, Wang X, Wang X, Zhang Y Sci Rep. 2022; 12(1):10082.

PMID: 35710698 PMC: 9203575. DOI: 10.1038/s41598-022-14097-x.

References

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G . The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2007; 8(1):11-23. DOI: 10.1038/nrc2291. View

George S, Vishwamitra D, Manshouri R, Shi P, Amin H . The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget. 2014; 5(14):5750-63. PMC: 4170597. DOI: 10.18632/oncotarget.2170. View

Blum K . CD30: seeing is not always believing. Blood. 2015; 125(9):1358-9. DOI: 10.1182/blood-2015-01-622480. View

Miano V, Ferrero G, Reineri S, Caizzi L, Annaratone L, Ricci L . Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer. Oncotarget. 2015; 7(3):3201-16. PMC: 4823100. DOI: 10.18632/oncotarget.6420. View

Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau I . Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Oncotarget. 2015; 6(30):30149-64. PMC: 4745787. DOI: 10.18632/oncotarget.4999. View

Choudhari R, Minero V, Menotti M, Pulito R, Brakebusch C, Compagno M . Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice. Blood. 2016; 127(10):1297-306. PMC: 4786839. DOI: 10.1182/blood-2015-11-683052. View

Hirata H, Hinoda Y, Shahryari V, Deng G, Nakajima K, Tabatabai Z . Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Cancer Res. 2015; 75(7):1322-31. PMC: 5884967. DOI: 10.1158/0008-5472.CAN-14-2931. View

Desjobert C, Renalier M, Bergalet J, Dejean E, Joseph N, Kruczynski A . MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood. 2011; 117(24):6627-37. DOI: 10.1182/blood-2010-09-301994. View

10.

Aveic S, Pantile M, Seydel A, Esposito M, Zanon C, Li G . Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. Oncotarget. 2016; 7(5):5646-63. PMC: 4868711. DOI: 10.18632/oncotarget.6778. View

11.

Seton-Rogers S . Non-coding RNAs: The cancer X factor. Nat Rev Cancer. 2013; 13(4):224-5. DOI: 10.1038/nrc3489. View

12.

Zhang Q, Wang H, Liu X, Wasik M . STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med. 2007; 13(11):1341-8. DOI: 10.1038/nm1659. View

13.

Xie X, Tang B, Xiao Y, Xie R, Li B, Dong H . Long non-coding RNAs in colorectal cancer. Oncotarget. 2015; 7(5):5226-39. PMC: 4868682. DOI: 10.18632/oncotarget.6446. View

14.

Seton-Rogers S . Non-coding RNA: Stressed to bits. Nat Rev Cancer. 2015; 15(6):320. DOI: 10.1038/nrc3966. View

15.

Chung I, Chen C, Lin Y, Chi H, Huang Y, Tai P . Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer. Oncotarget. 2015; 6(17):15050-64. PMC: 4558135. DOI: 10.18632/oncotarget.3670. View

16.

ten Berge R, Oudejans J, Ossenkoppele G, Pulford K, Willemze R, Falini B . ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000; 53(6):445-50. PMC: 1731216. DOI: 10.1136/jcp.53.6.445. View

17.

Hoareau-Aveilla C, Valentin T, Daugrois C, Quelen C, Mitou G, Quentin S . Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. J Clin Invest. 2015; 125(9):3505-18. PMC: 4588301. DOI: 10.1172/JCI78488. View

18.

Fatica A, Bozzoni I . Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2013; 15(1):7-21. DOI: 10.1038/nrg3606. View

19.

Dejean E, Renalier M, Foisseau M, Agirre X, Joseph N, de Paiva G . Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia. 2011; 25(12):1882-90. DOI: 10.1038/leu.2011.168. View

20.

Ceccon M, Merlo M, Mologni L, Poggio T, Varesio L, Menotti M . Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene. 2015; 35(29):3854-3865. PMC: 4907875. DOI: 10.1038/onc.2015.456. View